Wave Life Sci Ord Sh (WVE)

$7.34 -0.24 (-3.17%)
Market Cap 1.41B
Revenue (ttm) 42.73M
Net Income (ttm) -204.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -478.31%
Debt to Equity Ratio 0.00
Volume 4,337,200
Avg Vol 4,320,890
Day's Range N/A - N/A
Shares Out 188.26M
Stochastic %K 79%
Beta -1.32
Analysts Strong Sell
Price Target $25.86

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of...

Industry: Biotechnology
Sector: Healthcare
Phone: 65 6236 3388
Address:
Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore
BioPM1989
BioPM1989 Apr. 21 at 8:15 PM
$WVE A fine Haussecker sponsored development
0 · Reply
collegeballer48
collegeballer48 Apr. 21 at 7:44 PM
$WVE and we’re back to $7.30
0 · Reply
Goingthewrongdirection
Goingthewrongdirection Apr. 21 at 1:31 PM
$WVE Very Quiet!
0 · Reply
BioRich
BioRich Apr. 16 at 1:58 PM
$OCUL Rare Insight... @BioRich Current Top 20: 1) GUTS 2) MIST 3) IBRX 4) UEC 5) KYTX 6) OCUL 7) $DAVE 8) $WVE 9) $MLTX 10) $CAPR 11) LPCN 12) KTOS 13) ADMA 14) TGTX 15) VKTX 16) BBAI 17) CADL 18) TLSA 19) SNDX 20) NVAX Follow/Subscribe for more insights and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
cninc
cninc Apr. 14 at 10:33 PM
$WVE 𝐑𝐚𝐲𝐦𝐨𝐧𝐝 𝐉𝐚𝐦𝐞𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: @WaveLifeSci's CEO @PaulBolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month https://x.com/RNAiAnalyst/status/2044153460631740731?s=20
0 · Reply
Autolus_Freakk
Autolus_Freakk Apr. 14 at 2:43 PM
$WVE Dead
0 · Reply
collegeballer48
collegeballer48 Apr. 14 at 2:26 PM
$WVE hits $7.30 area and gets smacked up!
0 · Reply
PepCF
PepCF Apr. 14 at 1:16 PM
$WVE .
0 · Reply
Aclark314
Aclark314 Apr. 13 at 7:50 PM
$WVE
0 · Reply
Tony_37
Tony_37 Apr. 13 at 6:05 PM
$WVE : In $7.11 💎🚀💵
0 · Reply
Latest News on WVE
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Apr 21, 2026, 4:01 PM EDT - 5 hours ago

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Apr 15, 2026, 4:01 PM EDT - 6 days ago

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Wave Life Sciences stock crash: why analyst sees a buying opportunity

Mar 26, 2026, 3:00 PM EDT - 26 days ago

Wave Life Sciences stock crash: why analyst sees a buying opportunity

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

Mar 26, 2026, 11:25 AM EDT - 26 days ago

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 26, 2026, 10:28 AM EDT - 26 days ago

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Mar 26, 2026, 9:33 AM EDT - 26 days ago

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Mar 26, 2026, 7:30 AM EDT - 26 days ago

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 6 weeks ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA RGNX

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Mar 5, 2026, 8:30 AM EST - 6 weeks ago

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:30 AM EST - 7 weeks ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb 19, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

Feb 2, 2026, 2:16 PM EST - 2 months ago

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

GSK

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Feb 2, 2026, 7:30 AM EST - 2 months ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 12, 2026, 7:30 AM EST - 3 months ago

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 3 months ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Why Did Wave Life Sciences Surge 147%?

Dec 15, 2025, 6:30 AM EST - 4 months ago

Why Did Wave Life Sciences Surge 147%?

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 9, 2025, 9:50 PM EST - 4 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

What's Going On With Wave Life Sciences Stock Tuesday?

Dec 9, 2025, 2:11 PM EST - 4 months ago

What's Going On With Wave Life Sciences Stock Tuesday?

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 4 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 8, 2025, 7:30 AM EST - 4 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Dec 7, 2025, 4:00 PM EST - 4 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Nov 11, 2025, 11:46 AM EST - 5 months ago

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 5 months ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 7, 2025, 8:30 AM EST - 5 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 PM EST - 5 months ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Nov 4, 2025, 8:30 AM EST - 6 months ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 10:50 PM EDT - 6 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 6 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 18, 2025, 8:30 AM EDT - 7 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Sep 3, 2025, 1:28 PM EDT - 8 months ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

GSK

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Sep 3, 2025, 7:30 AM EDT - 8 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 7:30 AM EDT - 9 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jul 23, 2025, 8:30 AM EDT - 9 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

Jun 20, 2025, 4:01 PM EDT - 10 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:30 AM EDT - 11 months ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025, 8:00 AM EDT - 11 months ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 1 year ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Mar 26, 2025, 10:21 AM EDT - 1 year ago

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 7:30 AM EST - 1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 25, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Feb 6, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Dec 23, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Oct 30, 2024, 4:45 PM EDT - 1 year ago

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Oct 16, 2024, 2:43 PM EDT - 1 year ago

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

CSCO GWW SAP WLK

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

Oct 16, 2024, 11:19 AM EDT - 1 year ago

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

BioPM1989
BioPM1989 Apr. 21 at 8:15 PM
$WVE A fine Haussecker sponsored development
0 · Reply
collegeballer48
collegeballer48 Apr. 21 at 7:44 PM
$WVE and we’re back to $7.30
0 · Reply
Goingthewrongdirection
Goingthewrongdirection Apr. 21 at 1:31 PM
$WVE Very Quiet!
0 · Reply
BioRich
BioRich Apr. 16 at 1:58 PM
$OCUL Rare Insight... @BioRich Current Top 20: 1) GUTS 2) MIST 3) IBRX 4) UEC 5) KYTX 6) OCUL 7) $DAVE 8) $WVE 9) $MLTX 10) $CAPR 11) LPCN 12) KTOS 13) ADMA 14) TGTX 15) VKTX 16) BBAI 17) CADL 18) TLSA 19) SNDX 20) NVAX Follow/Subscribe for more insights and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
cninc
cninc Apr. 14 at 10:33 PM
$WVE 𝐑𝐚𝐲𝐦𝐨𝐧𝐝 𝐉𝐚𝐦𝐞𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: @WaveLifeSci's CEO @PaulBolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month https://x.com/RNAiAnalyst/status/2044153460631740731?s=20
0 · Reply
Autolus_Freakk
Autolus_Freakk Apr. 14 at 2:43 PM
$WVE Dead
0 · Reply
collegeballer48
collegeballer48 Apr. 14 at 2:26 PM
$WVE hits $7.30 area and gets smacked up!
0 · Reply
PepCF
PepCF Apr. 14 at 1:16 PM
$WVE .
0 · Reply
Aclark314
Aclark314 Apr. 13 at 7:50 PM
$WVE
0 · Reply
Tony_37
Tony_37 Apr. 13 at 6:05 PM
$WVE : In $7.11 💎🚀💵
0 · Reply
ScorpionScarlet
ScorpionScarlet Apr. 13 at 5:08 PM
$WVE don't be sad. Went down to 5.80 now up to 7🥳🥳🥳💕what more does one want? Be happy🍾
0 · Reply
collegeballer48
collegeballer48 Apr. 13 at 1:48 PM
$WVE more paint dry. Consolidation and support over $7 but slow moving and volume has been below average the past few trading days.
0 · Reply
mimiwor
mimiwor Apr. 13 at 8:05 AM
$WVE He is from Havard.
0 · Reply
Xplay888
Xplay888 Apr. 13 at 3:11 AM
$WVE Green in the sea of Red tomorrow. Looking eager for $7.50+++ Tomorrow.
0 · Reply
mimiwor
mimiwor Apr. 10 at 7:16 PM
$WVE adding
0 · Reply
Xplay888
Xplay888 Apr. 9 at 4:43 PM
$WVE Let's hit $7.30!... let's go....
0 · Reply
MulaBagz
MulaBagz Apr. 9 at 1:25 PM
$WVE
0 · Reply
Xplay888
Xplay888 Apr. 9 at 7:48 AM
$WVE Let's break $7.30... & touch $7.50..... Let's go.
0 · Reply
StonkMaster101
StonkMaster101 Apr. 8 at 6:39 PM
$WVE what’s going on here???
1 · Reply
Goingthewrongdirection
Goingthewrongdirection Apr. 8 at 2:14 PM
$WVE This should be up much higher today.
0 · Reply
B_B_
B_B_ Apr. 8 at 1:09 PM
$WVE (2/2) Wave Life Sciences develops oligonucleotide-based therapies using its proprietary PRISM platform, which designs stereopure oligonucleotides for enhanced potency and durability. You get precise control over RNA molecules to silence faulty genes or edit them directly, addressing root causes of genetic disorders. This approach sets it apart in a crowded biotech field where many rely on less specific methods. The company's pipeline spans neurology, metabolic diseases, and infectious diseases, with lead candidates like wve-003 for Huntington's disease and wve-006 for AATD liver disease advancing through clinical stages. ... Track Huntington's data and AATD progress closely—these could catalyze 2x or more upside. Balance with position sizing to manage volatility. ... https://www.ad-hoc-news.de/boerse/news/ueberblick/wave-life-sciences-stock-why-it-s-drawing-biotech-investor-attention-now/69104286#google_vignette
2 · Reply
B_B_
B_B_ Apr. 8 at 1:09 PM
$WVE (1/2) Wave Life Sciences stock: Why it's drawing biotech investor attention now 08.04.2026 | ad-hoc-news.de Wave Life Sciences is advancing RNA therapies that could reshape treatments for genetic diseases—making it a stock worth watching for global investors seeking biotech breakthroughs. With innovative platforms targeting unmet needs, here's what you need to know before deciding. ... You're scanning the biotech landscape for the next big opportunity, and Wave Life Sciences keeps popping up. This company is pushing boundaries in RNA editing and silencing technologies, aiming to tackle diseases like Huntington's and alpha-1 antitrypsin deficiency that have long frustrated traditional drug developers. ...
0 · Reply